Skip to content

CJC-1295 (without DAC)

Tags: GHRH analogue, Mod-GRF, Growth Hormone

Quick Summary

CJC-1295 (without DAC), also called Modified GRF 1-29 or Mod GRF 1-29, is a short-acting GHRH analogue that produces pulsatile growth hormone release with a plasma half-life around 30 minutes.

Overview

CJC-1295 without DAC is designed to trigger discrete GH spikes that more closely mimic natural physiology, reducing receptor desensitization risk compared with longer-acting DAC-modified variants.

Key Benefits

  • Restores physiological GH pulsatility
  • Minimal receptor desensitization when dosed appropriately
  • Short half-life allows fine control over GH pulses

Mechanism of Action

CJC-1295 (no DAC) binds GHRH receptors on pituitary somatotrophs, raising intracellular cAMP and prompting timed GH secretion in pulses rather than continuous exposure.

Molecular Information

  • Weight: 3,367.97 Da
  • Length: 30 amino acids
  • Type: GHRH analogue (Mod GRF 1-29)
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

Modified GRF(1-29) with increased stability; requires frequent dosing due to short half-life.

Research Indications

  • Growth hormone pulse restoration
  • Anti-aging / wellness support (IGF-1 elevation)
  • Support pituitary-somatotroph function without suppression

Research Protocols

Goal Dose Frequency Route
Anti-Aging / Wellness 100 mcg 2× daily (morning + bedtime) Subcutaneous
Body Composition 100–150 mcg 3× daily (morning, post-workout, bedtime) Subcutaneous
Maximum GH Release 200 mcg 2–3× daily with a GHRP Subcutaneous
Sleep Enhancement 100–200 mcg Once at bedtime Subcutaneous

Timing: Administer at least 30 minutes away from food for best absorption. Morning dose on waking and evening dose before bed are commonly used for ideal pulsatile responses.

Interactions

Compatible / Complementary

  • Ipamorelin — Synergistic
  • GHRP-6 / GHRP-2 — Synergistic
  • MK-677 (Ibutamoren) — Compatible

Monitor

  • Hexarelin — Monitor combination (potential overstimulation)

Avoid

  • CJC-1295 with DAC — Avoid combination

How to Reconstitute (practical notes)

  1. Use bacteriostatic water and sterile technique.
  2. For a 2 mg vial, drawing 2 mL BAC water yields approximately 100 mcg per 10 units (example concentrations vary — calculate precisely).
  3. Inject water slowly down the vial wall and gently roll to mix; do not shake.
  4. Solution should be clear; cloudy or discolored solution indicates degradation — discard.
  5. Label vial with reconstitution date and concentration and refrigerate immediately.

Quality Indicators

Positive Signs

  • COA showing >98% purity
  • Proper cold-chain shipping and vacuum-sealed vials

Warning Signs

  • Pre-mixed solutions (prefer lyophilized powder)

What to Expect

  • Day 1–7: Improved sleep quality, vivid dreams may occur
  • Week 2–4: Better recovery, reduced post-exercise soreness
  • Week 4–8: Noticeable skin improvements and early body-composition changes
  • Week 8–12+: Gradual lean-mass gains and reduced body fat with sustained use

Side Effects & Safety

  • Generally well tolerated at recommended doses
  • Possible transient flushing or warmth after injection
  • Monitor blood glucose in people with diabetes (GH affects insulin sensitivity)
  • Avoid use with active cancer or in those with diabetic retinopathy or severe renal disease

References

Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006)

  • Humans | 100–200 mcg | Single dose | 12 subjects

Growth Hormone Pulsatility with Mod GRF 1-29 (2008)

  • Humans | 100 mcg 3× daily | 30 days | 24 subjects

Comparative Analysis: CJC-1295 vs Native GHRH (2010)

  • In vitro + Human | Various doses | Receptor binding assays